Speirs V, Kerin M J
Medical Research Laboratory and Academic Surgical Unit, University of Hull, Hull, UK.
Br J Surg. 2000 Apr;87(4):405-9. doi: 10.1046/j.1365-2168.2000.01402.x.
Endocrine therapy for breast cancer is now well established and with the identification of a second oestrogen receptor, ERbeta, 3 years ago it is timely to review the possible significance of this receptor in breast cancer management.
An up-to-date review of the current literature concerning the role and possible implications of ERbeta in human breast cancer was undertaken.
Wild-type and variant ERbeta are expressed in human breast tumours. Expression of ERbeta correlates with accepted prognostic indicators including lymph node status and tumour grade. Furthermore, levels of ERbeta messenger RNA alter during carcinogenesis and are upregulated in breast tumours that develop antioestrogen resistance.
ERbeta has potential as a novel clinical prognostic marker in breast cancer, particularly in determining tumours that are resistant to tamoxifen.
乳腺癌的内分泌治疗目前已得到充分确立，并且随着3年前第二种雌激素受体——雌激素受体β（ERβ）的发现，现在是时候审视该受体在乳腺癌治疗中的潜在意义了。
对当前有关ERβ在人类乳腺癌中的作用及可能影响的文献进行了最新综述。
野生型和变异型ERβ在人类乳腺肿瘤中均有表达。ERβ的表达与包括淋巴结状态和肿瘤分级在内的公认预后指标相关。此外，ERβ信使核糖核酸的水平在致癌过程中会发生变化，并且在产生抗雌激素耐药性的乳腺肿瘤中会上调。
ERβ有潜力成为乳腺癌一种新的临床预后标志物，尤其是在确定对他莫昔芬耐药的肿瘤方面。
